KELUN PHARMA: With the arrival of the peak season in the fourth quarter, Yili Chuanning Bio's performance is expected to improve

Zhitong
2025.09.01 03:03

KELUN PHARMA stated during an institutional research that the demand side of the antibiotic sector is currently stabilizing. Despite price fluctuations, the company has a clear cost advantage. Meanwhile, Yili Chuanning Bio has made substantial progress in cost reduction through artificial intelligence. Affected by the market price of penicillin, Yili Chuanning Bio's overall performance is expected to decline significantly compared to last year. Currently, the price of penicillin has bottomed out, and with the arrival of the peak season in the fourth quarter, performance is expected to improve. By 2026, with the volume production of synthetic biology products and the rebound in penicillin prices, Yili Chuanning Bio's operating performance and profits are expected to have significant room for improvement

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer